Group 1 - The Hang Seng Technology Index opened lower and fluctuated, dropping over 1.5% at one point, and closed down approximately 0.34% at 5349.48 points [1] - The Hang Seng Technology ETF (520570) experienced active trading with a transaction amount of about 115 million yuan and a turnover rate of approximately 4.41%, indicating intense market competition [1] - The ETF saw a net subscription of about 77.85 million yuan yesterday, ranking 17th out of 212 in net inflows among cross-border ETFs, with a cumulative net inflow of approximately 78.75 million yuan over the past five days, reflecting a strong long-term investment interest in the Hong Kong tech sector [1] Group 2 - Analysts believe that the current valuation of the Hong Kong tech sector is at a near five-year low, with the Hang Seng Technology Index showing a historical high in the yield gap compared to the ChiNext Index, indicating a high margin of safety [1] - The Hong Kong tech sector is positioned at the core of AI application and commercialization, with strong earnings growth certainty, supported by expectations of a stable yuan and a weak US dollar [1] - Southbound funds saw a net purchase of approximately 6.16 billion HKD on February 4, with significant net buying in tech giants like Tencent and Alibaba, and over 8 billion HKD on February 5, indicating a growing interest from mainland investors in Hong Kong tech assets [1]

Group 1 - The core viewpoint of the news highlights the strong performance of the Hang Seng Biotechnology ETF (159615), which surged over 4% and is experiencing active trading, with a turnover of 48.91 million yuan and a turnover rate of 14.78% [1] - The Hang Seng Biotechnology Index increased by 3.14%, with significant gains in constituent stocks such as 3SBio, which rose by 29.93%, and other companies like Rongchang Bio and Innovent Biologics also showing positive movements [1] - 3SBio announced a licensing agreement with Pfizer for the PD-1/VEGF bispecific antibody SSGJ-707, which includes an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion, along with a double-digit percentage royalty on net sales in licensed regions [1] Group 2 - Guojin Securities emphasizes that the innovative drug sector within the pharmaceutical industry is the most noteworthy area for investment, with a focus on capturing opportunities throughout 2025 [2] - The report indicates that leading innovative drug companies are expected to see continued commercial sales and business development performance, particularly in oncology, autoimmune diseases, and chronic conditions, which will support growth and valuation recovery for leading companies in these segments [2] - The news mentions related investment products, including the Hang Seng Biotechnology ETF (159615) and other ETFs, which aim to help investors seize opportunities in the Hong Kong stock market [2]